Positive trial data for Kodiak Sciences Inc’s eye drug drives bullish sentiment as stocks have been trading up by 176.45 percent
Click Here for a Millionaire's POV on Trading KOD
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- UBS reiterates a Buy on Kodiak Sciences, calling out phase III wet AMD trials for tarcocimab and KSI-501 as likely non-inferior to Eylea and lifting upside potential with an $80 target.
- Multiple near-term catalysts for KOD cluster around September topline data, an AAO presentation in October, and further readouts in December, drawing momentum-focused traders.
- Goldman Sachs resumes coverage of Kodiak Sciences with a Neutral rating and a $36 target, staying cautious even as it praises the improving biotech backdrop.
- Pivotal Phase 3 DAYBREAK topline results for Zenkuda (tarcocimab tedromer) and KSI-501 in wet AMD will be presented on 2026/09/28, spotlighting Kodiak’s late-stage retina pipeline.
Live Update At 16:46:51 EDT: On Monday, September 28, 2026 Kodiak Sciences Inc stock [NASDAQ: KOD] is trending up by 176.45%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Kodiak Sciences (KOD) just went from sleepy mid-30s price action to a face-ripping move, closing at $89.92 after trading as high as $95.77. A few sessions ago, KOD was grinding around $32–$35. That means traders are looking at a near triple from recent levels, almost all packed into one explosive catalyst run.
Zoom in on the intraday tape and you see classic momentum behavior. KOD opened around $61.71 and immediately saw heavy volatility, flushing toward $60.49, then grinding and surging in waves all the way into the mid-90s before settling just under $90. Range like that tells you one thing: this is now a trader’s stock.
More Breaking News
- MEDS Stock Explodes As Helomics Deal Rewires The Story
- SOFI Stock Wobbles As Insider Form 144 Flags Potential Selling
- MP Stock Pullback Has Active Traders Studying The Range
- RKT Stock Drifts Lower As Traders Weigh Mortgage Headwinds
Fundamentally, Kodiak’s numbers scream “clinical-stage biotech.” The latest quarterly report shows a net loss of about -$65.6M and operating cash outflow of roughly -$46.2M. Return on equity and assets are sharply negative, and price-to-book is sky-high around 33x. On the plus side, Kodiak Sciences still holds about $125.9M in cash with working capital near $78.6M and a current ratio of 2.5, giving KOD breathing room to fund trials. For traders, that mix—heavy losses but solid cash and huge news catalysts—sets up a pure sentiment and data-driven trade.
Why Traders Are Watching KOD Now
KOD is front and center on many screens because the story just shifted from “promising pipeline” to “decision time.” UBS fired up the move by reiterating a Buy rating on Kodiak Sciences and laying out a clear bullish roadmap. The bank argues that KOD’s phase III wet AMD trials for tarcocimab and KSI-501 are likely to show non-inferiority versus Eylea, the current standard. Add the potential for extended dosing intervals and you get a compelling narrative: similar vision outcomes, fewer injections, and a shot at real market share.
UBS backs that view with an $80 price target that, ironically, has already been challenged by the latest spike, with KOD now trading near $90. That tells traders the market is now pricing in even more optimism than UBS had on paper, at least ahead of the key data. It also means any disappointment could unwind fast.
Goldman Sachs offers the brake pedal in this setup. While it resumed coverage of Kodiak Sciences with a Neutral rating and a $36 target, it still notes a friendlier biotech environment—more M&A, better clinical wins, and a more supportive regulator. The message: the sector tailwind is real, but Goldman is not ready to chase KOD’s upside the way UBS is.
Everything circles back to the DAYBREAK trial. On 2026/09/28, Kodiak Sciences will present pivotal Phase 3 topline results for Zenkuda (tarcocimab tedromer) and KSI-501 in wet AMD, plus timelines for more Phase 3 readouts in other retinal indications. For traders, that is the definition of a binary event. KOD now trades like a lottery ticket tied to those data, with premium-sized moves both intraday and across days.
Conclusion
Right now, KOD is the kind of stock momentum traders study for years. You have a late-stage biotech, a packed catalyst calendar, and big banks disagreeing on upside. UBS talks up Kodiak Sciences with an $80 target and confidence in the wet AMD trials. Goldman Sachs stays Neutral at $36, even as it acknowledges the stronger biotech backdrop. The tape isn’t waiting for consensus—KOD has already exploded from the low 30s to near $90 into the DAYBREAK readout.
Under the hood, Kodiak Sciences is still burning cash and posting steep losses. That is normal for a clinical-stage biotech, but it means KOD’s current valuation is almost entirely about expectations for Zenkuda and KSI-501. If the DAYBREAK data show strong non-inferiority to Eylea and support less frequent dosing, the bullish scenario many traders are betting on gains serious weight. If the data disappoint, the downside can be just as violent as the run-up.
For active traders, this is a textbook catalyst setup: clear dates, defined risk, and wild volatility. As Tim Sykes loves to remind his students, “Pattern plus catalyst plus discipline is everything—react to the price action, don’t predict it.” As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” KOD now sits in that zone where disciplined planning, strict risk management, and fast reactions matter more than ever. This is educational and research material only, but Kodiak Sciences is giving the trading community a live masterclass in how momentum meets biotech risk.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.